Avatar
Yashbhardwaj

0 Following 0 Followers
1
The Neurofibromatosis newsletter provides a complete picture of the Neurofibromatosis market landscape, ongoing clinical trials, pipeline therapies that are exp...
1
The T cell Lymphoma newsletter encapsulates the cell Lymphoma treatment sphere, including the current, marketed and upcoming, novel drugs in the TCL therapeutic...
1
Axial Spondyloarthritis market landscape in the newsletter consisting of currently marketed axSpA drugs, market trends, historical and current epidemiology, ong...
1
The End-Stage Renal Disease newsletter also comprises the End-Stage Renal Disease market landscape, ongoing clinical trials with significant pharmaceuticals inv...
1
Explore more about the Cocaine Use Disorder condition, its causes, signs and symptoms, epidemiological insights and currently available therapeutic options thro...
1
The Cardiovascular Disease Devices whitepaper not only carries a snippet as to what are the most potential factors that seem to promote the CVD industry, but al...
1
The Lupus Nephritis newsletter encompasses the Lupus Nephritis treatment landscape constituting the current, marketed and upcoming, novel drugs in the Lupus Nep...
1
Neuromyelitis Optica Spectrum Disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord which causes inflammation in the optic nerve and spinal cord.
Currently, the Neuromyelitis Optica Spectrum Disorder domain constitutes a robust pipeline with more than 20 drugs existing in the NMOSD therapeutic landscape, out of which 3 are marketed, and 17 are under different phases of development.
DelveInsight presents a new addition to its newsletter edition that focuses on the…
1
The Virtual Clinical Trials whitepaper includes an overview, comparison between traditional and virtual clinical trial, impact of COVID-19 on clinical trial, pa...
1
The Myelodysplastic Syndrome (MDS) Market Analysis Whitepaper highlights how several emerging therapies in the pipeline might impact the current treatment regim...